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Staging of non-small-cell lung cancer with integrated
positron-emission tomography and computed tomography
Abstract
BACKGROUND: We compared the diagnostic accuracy of integrated positron-emission tomography
(PET) and computed tomography (CT) with that of CT alone, that of PET alone, and that of
conventional visual correlation of PET and CT in determining the stage of disease in non-small-cell lung
cancer. METHODS: In a prospective study, integrated PET-CT was performed in 50 patients with
proven or suspected non-small-cell lung cancer. CT and PET alone, visually correlated PET and CT, and
integrated PET-CT were evaluated separately, and a tumor-node-metastasis (TNM) stage was assigned
on the basis of image analysis. Nodal stations were identified according to the mapping system of the
American Thoracic Society. The standard of reference was histopathological assessment of tumor stage
and node stage. Extrathoracic metastases were confirmed histopathologically or by at least one other
imaging method. A paired sign test was used to compare integrated PET-CT with the other imaging
methods. RESULTS: Integrated PET-CT provided additional information in 20 of 49 patients (41
percent), beyond that provided by conventional visual correlation of PET and CT. Integrated PET-CT
had better diagnostic accuracy than the other imaging methods. Tumor staging was significantly more
accurate with integrated PET-CT than with CT alone (P=0.001), PET alone (P<0.001), or visual
correlation of PET and CT (P=0.013); node staging was also significantly more accurate with integrated
PET-CT than with PET alone (P=0.013). In metastasis staging, integrated PET-CT increased the
diagnostic certainty in two of eight patients. CONCLUSIONS: Integrated PET-CT improves the
diagnostic accuracy of the staging of non-small-cell lung cancer.
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background
 
We compared the diagnostic accuracy of integrated positron-emission tomography
(PET) and computed tomography (CT) with that of CT alone, that of PET alone, and that
of conventional visual correlation of PET and CT in determining the stage of disease in
non–small-cell lung cancer.
 
methods
 
In a prospective study, integrated PET–CT was performed in 50 patients with proven or
suspected non–small-cell lung cancer. CT and PET alone, visually correlated PET and
CT, and integrated PET–CT were evaluated separately, and a tumor–node–metastasis
(TNM) stage was assigned on the basis of image analysis. Nodal stations were identified
according to the mapping system of the American Thoracic Society. The standard of
reference was histopathological assessment of tumor stage and node stage. Extratho-
racic metastases were confirmed histopathologically or by at least one other imaging
method. A paired sign test was used to compare integrated PET–CT with the other im-
aging methods.
 
results
 
Integrated PET–CT provided additional information in 20 of 49 patients (41 percent),
beyond that provided by conventional visual correlation of PET and CT. Integrated PET–
CT had better diagnostic accuracy than the other imaging methods. Tumor staging was
significantly more accurate with integrated PET–CT than with CT alone (P=0.001), PET
alone (P<0.001), or visual correlation of PET and CT (P=0.013); node staging was also
significantly more accurate with integrated PET–CT than with PET alone (P=0.013). In
metastasis staging, integrated PET–CT increased the diagnostic certainty in two of eight
patients.
 
conclusions
 
Integrated PET–CT improves the diagnostic accuracy of the staging of non–small-cell
lung cancer.
abstract
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omputed tomography (ct) has an
 
important role in the initial determination
of the stage of disease in lung cancer. CT
provides excellent morphologic information on the
extent of disease but has limited ability to differen-
tiate between benign and malignant lesions in an
organ or in lymph nodes. Whole-body positron-
emission tomography (PET) with fludeoxyglucose
F 18 ([
 
18
 
F]fluoro-2-deoxy-
 
d
 
-glucose) has a higher
rate of detection of mediastinal lymph-node metas-
tases as well as of extrathoracic metastases.
 
1-6
 
 It
has also proved effective in the management of
non–small-cell lung cancer.
 
7-10
 
 Since commercial
PET scanners provide nominal spatial resolution of
4.5 to 6.0 mm in the center of the axial field of view,
even lesions that are less than 1 cm in diameter can
be detected on the basis of an increased uptake of
fludeoxyglucose F 18.
However, fludeoxyglucose F 18 is also taken up
by muscles and inflammatory processes.
 
11-13
 
 Fur-
thermore, PET provides imprecise information on
the exact location of focal abnormalities. Thus, even
if the results of PET and CT are visually correlated,
the precise location of lesions is sometimes difficult
to determine. Recently, integrated PET–CT scanners
have been introduced.
 
14
 
 Initial results in oncology
have been encouraging.
 
15-17
 
 Therefore, we prospec-
tively compared the accuracy of integrated PET–CT
with that of other imaging methods in staging non–
small-cell lung cancer.
 
patients
 
Fifty patients with proven or suspected non–small-
cell lung cancer were enrolled in the study at the
University Hospital of Zurich, Zurich, Switzerland.
Our institution is a teaching and tertiary care hospi-
tal and a major referral site for patients with cancer.
Thoracic surgeons at the facility have been using
PET routinely for preoperative assessment of dis-
ease stage since 1994. All patients underwent con-
ventional staging based on a review of the medical
history, physical findings, and results of blood tests,
bronchoscopy, and contrast-enhanced CT of the
chest and upper abdomen, and all also underwent
integrated whole-body PET–CT. All consecutive pa-
tients referred for surgery between July 2001 and
February 2002 were included in the study after giv-
ing written informed consent in accordance with
the regulations of the institutional review board.
One patient was excluded from further study be-
cause histologic analysis revealed mucosa-associ-
ated lymphoma. Thus, 49 patients (28 men and 21
women) with a mean age of 62 years (range, 46 to
81) remained in the study. Histologic analysis re-
vealed adenocarcinoma in 28 patients, squamous-
cell carcinoma in 13, and large-cell carcinoma in 8.
 
integrated pet and ct
 
Patients received an intravenous injection of 350 to
400 MBq of fludeoxyglucose F 18 and then rested
for approximately 50 minutes before undergoing
imaging. Image acquisition was performed with
use of an integrated PET–CT device (Discovery LS,
GE Medical Systems) consisting of an Advance NX
 
i
 
PET scanner and a four-slice Light Speed Plus CT
scanner. The axes of both systems were mechani-
cally aligned so that shifting the examination table
by 60 cm moved the patient from the CT into the
PET gantry. The resulting PET and CT images were
coregistered on hardware. 
An unenhanced CT image was obtained from
the patient’s head to the pelvic floor with use of
a standardized protocol involving 140 kV, 80 mA,
a tube-rotation time of 0.5 second per rotation, a
pitch of 6, and a section thickness of 5 mm, which
was matched to the section thickness of the PET
images.
 
17
 
 Immediately after CT, PET was performed
that covered the identical axial field of view. The
acquisition time for PET was 4 minutes per table
position and 24 minutes in all. Patients were in-
structed to hold their breath in normal expiration
for 22 seconds during the acquisition of the CT im-
ages and to breathe shallowly during the acquisi-
tion of the PET images.
 
18
 
 PET-image data sets were
reconstructed iteratively with segmented correc-
tion for attenuation with use of the CT data.
 
19,20
 
Coregistered images were displayed by means of
eNTEGRA software (GE Medical Systems).
 
surgery
 
Lung resections were performed with mediasti-
nal lymph-node dissection, which consisted of en-
bloc dissection of all nodes at stations 2 through
4 and 7 through 9 on the right side and of stations
4 through 9 on the left side, according to the map-
ping system of the American Thoracic Society.
 
21-23
 
Surgery was performed in 40 patients and consist-
ed of lung resection and mediastinal lymphade-
nectomy in 35 patients, exploratory thoracotomy in
3, and wedge resection in 2. Eight patients who pre-
sented with occult extrathoracic metastases and
one patient who had malignant cells in pleural flu-
c
methods
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id were excluded from surgery. In the two patients
who underwent wedge resection, lung function was
too limited for a lobectomy. Lymphadenectomy was
not performed in these patients, since mediastinal
lymph nodes were less than 5 mm on CT and PET
was negative for lymph-node involvement. Of the
three patients who underwent only exploratory tho-
racotomy, one had pleural dissemination and two
had infiltration of the aorta.
Four patients received adjuvant chemotherapy
because stage IIIA disease was found after medi-
astinoscopy. Three with N2 disease on tumor–
node–metastasis (TNM) staging had unquestion-
able stage T1 or T2 disease without any evidence
of chest-wall or mediastinal invasion. One patient
had a superior sulcus tumor with Pancoast’s syn-
drome. Complete pathological TNM staging was
performed in 35 patients and disease was classified
as stage IA in 10 patients, stage IB in 5, stage IIB in
6, stage IIIA in 9, and stage IIIB in 5.
 
assessment of extrathoracic metastases
 
After PET, extrathoracic focal abnormalities were
described according to their locations with the use
of integrated PET–CT. Further evaluation of sus-
pected metastases included biopsies or the use of
other imaging methods if biopsy was not ethically
justified.
 
statistical analysis
 
The images were prospectively analyzed by two
independent review boards whose members had
no knowledge of the patients’ clinical data or the
results of other imaging studies. Review Board A,
consisting of a nuclear-radiology physician and a
thoracic surgeon, first analyzed all CT images and
assigned a TNM stage. After reviewing the CT im-
ages for each patient, the reviewers assessed atten-
uation-corrected PET images. Thus, the reviewers
interpreted the PET images with the knowledge of
the CT findings and visually correlated the PET and
CT images. This approach was chosen because it
represents the standard practice of combined read-
ing of PET and CT images. On the basis of their vis-
ual correlation, the reviewers again assigned a TNM
stage. When a clear differentiation between differ-
ent tumor stages was not possible, both stages were
noted and the findings were deemed equivocal.
Review Board B, consisting of a different nuclear
physician and a different thoracic surgeon, analyzed
the attenuation-corrected PET images first and as-
signed a TNM stage. Then, the CT images, attenua-
tion-corrected PET images, and coregistered PET–
CT images were displayed together on the moni-
tor, and the reviewers again assigned a TNM stage.
When a clear differentiation between stages was
not possible, both stages were noted. After comple-
tion of the image analysis, the two review boards
showed the complete set of images to surgeons so
that surgery could be planned. Finally, TNM stages
based on the various imaging procedures were cor-
related with pathological stages.
Statistical analysis was carried out with SPSS
software. To identify any improvements in the ac-
curacy of staging associated with the use of coreg-
istered PET–CT, the tumor and node stage of each
imaging method was assessed by means of a score
ranging from 0 to 3, in which a score of 0 indicated
incorrect findings, a score of 1 equivocal but incor-
rect findings, a score of 2 correct but equivocal find-
ings, and a score of 3 correct findings. If the stage
was correctly determined (that is, it matched the
stage determined by conventional means), but ow-
ing to equivocal findings, more than one stage was
noted by the review board, the result was classified
as correct but equivocal. A paired sign test was used
to compare coregistered PET–CT with the other im-
aging methods. Because both a score of 0 and a
score of 1 were incorrect, we combined them in the
analysis and assigned them a score of 0. To address
the problem of multiple comparisons, Bonferroni’s
correction was applied. Thus, P values less than
0.017 were considered to indicate statistical signif-
icance. All P values are two-sided.
 
diagnostic accuracy
 
As compared with visual correlation, integrated
PET–CT provided 24 items of additional informa-
tion in 20 of 49 patients (41 percent). The addition-
al information consisted of the exact location of
lymph nodes in nine patients, precise evaluation of
chest-wall infiltration in three patients and of me-
diastinal invasion in three patients, correct differ-
entiation between tumor and peritumoral inflam-
mation or atelectasis in seven patients, and the exact
location of distant metastases in two patients. Over-
all, integrated PET–CT provided more accurate in-
formation on the stage of disease than did the other
two imaging methods, including visual correlation
of PET and CT. Statistically significant improve-
ments were found particularly in terms of the tumor
stage (Table 1).
results
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tumor staging
 
In 40 patients the tumor stage was confirmed his-
tologically. Table 2 shows the diagnostic accuracy
of the various imaging methods. Of 26 patients
whose tumor stage was classified correctly by means
of visual correlation of PET and CT, 24 patients were
also classified correctly by means of integrated
PET–CT, and in 2 the results were classified as cor-
rect but equivocal. Of the five patients in whom the
results of visual correlation of PET and CT were
classified as correct but equivocal, four were clas-
sified correctly on the basis of integrated PET–CT,
and in one the results remained correct but equivo-
cal. Of the nine patients classified incorrectly by
visual correlation of PET and CT, seven were classi-
fied correctly by integrated PET–CT, in one the re-
sults were classified as correct but equivocal, and in
one the results remained incorrect. In the evaluation
of chest-wall infiltration (Fig. 1) and mediastinal
invasion in 19 patients, PET–CT staging was cor-
rect in 16 patients (84 percent), correct but equivo-
cal in 3 (16 percent), and incorrect in none and vis-
ual correlation was correct in 10 (53 percent), correct
but equivocal in 5 (26 percent), and incorrect in
4 (21 percent).
 
node staging
 
In 37 patients, the node stage was confirmed histo-
logically. Table 3 shows the diagnostic accuracy of
the various imaging methods. Of 22 patients clas-
sified correctly by visual correlation of PET and CT,
21 patients were also classified correctly by inte-
grated PET–CT and in 1 the results were classified
as correct but equivocal. Of the four patients whose
results were classified as correct but equivocal on
the basis of visual correlation of PET and CT, all were
classified correctly by integrated PET–CT. Of the 11
patients whose results were classified as incorrect
on the basis of visual correlation of PET and CT,
5 were classified correctly by integrated PET–CT, and
6 remained incorrect. In one patient, PET–CT di-
agnosed contralateral mediastinal nodal metasta-
ses, but histologic analysis revealed inflammatory
changes. In two patients classified as having N1 dis-
ease on PET–CT, hilar extension of the tumor was
falsely interpreted as nodal metastases. In three pa-
tients, no increase in nodal radionuclide uptake in
the mediastinum could be detected by PET–CT, but
micrometastases were found on histologic analy-
sis in two. In one patient, no increased uptake was
found in a 5-mm lymph node. In one other patient,
a small focal abnormality was identified at the apex
of the thorax (Fig. 2). However, the precise loca-
tion of the abnormality could not be identified with
PET, CT, or visual correlation of PET and CT. Inte-
grated PET–CT showed that the focal abnormality
was in a normal-sized supraclavicular lymph node.
This information enabled the surgeons to perform
a straightforward resection of this lesion, and a
5-mm metastatic lymph node was confirmed his-
tologically.
 
* The paired sign test was used to calculate P values. Stag-
es assigned on the basis of CT alone, PET alone, and PET 
and CT were assessed by Review Board A, and stages as-
signed on the basis of integrated PET–CT were assessed 
by Review Board B.
 
† The P value was significant after Bonferroni’s correction.
 
Table 1. Comparison of the Diagnostic Accuracy
of Integrated PET–CT with CT Alone, PET Alone, 
and Visual Correlation of PET and CT Images.*
Variable P Value
Tumor stage (n=40)
 
PET–CT vs. CT alone 0.001†
PET–CT vs. PET alone <0.001†
PET–CT vs. visual correlation of PET
and CT
0.013†
 
Node stage (n=37)
 
PET–CT vs. CT alone 0.12
PET–CT vs. PET alone 0.013†
PET–CT vs. visual correlation of PET
and CT
0.021
 
Table 2. Diagnostic Accuracy of the Imaging Methods with Respect 
to Tumor Stage in 40 Patients.
Imaging Method
Classification 
Correct 
(Score of 3)
Classification 
Correct 
but Equivocal 
(Score of 2)
Classification 
Incorrect 
(Score of
0 or 1)
 
no. of patients (%)
 
CT alone 23 (58) 8 (20) 9 (22)
PET alone 16 (40) 16 (40) 8 (20)
Visual correlation of PET and CT 26 (65) 5 (12) 9 (22)
Integrated PET–CT 35 (88) 4 (10) 1 (2)
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metastasis staging
 
In 8 of 49 patients (16 percent), PET detected un-
suspected extrathoracic focal abnormalities sug-
gestive of metastases. PET precisely determined the
location of these lesions in six: three patients with
bone metastases, one patient with adrenal metas-
tasis, and two patients with cerebral dissemination
of the disease. In two other patients, PET detected
focal abnormalities in the pelvic region but could
not pinpoint their location. Visual correlation of
the CT images with the PET images did not reveal
any abnormality in this region. Integrated PET–CT
showed that the focal abnormalities were in the
pelvic bone in both patients.
 
interobserver variability
 
To assess the variability of staging between the two
teams of reviewers, we compared the kappa values
of the PET ratings of both review boards. The kap-
pa value was 0.56 for the tumor stage and 0.55 for
the node stage. No significant difference in the di-
agnostic accuracy of PET findings was found be-
tween the two review boards (P=0.06 for tumor
stage and P=1.0 for node stage).
Our results suggest that integrated PET–CT is su-
perior to PET alone, CT alone, or visual correlation
of PET with CT in determining the stage of disease
in non–small-cell lung cancer. Significant improve-
ments in tumor staging were found with integrated
PET–CT. The anatomical correlation of the radio-
nuclide uptake made possible a more precise delin-
eation of the location of the primary tumor. Integrat-
ed PET–CT improved the diagnosis of chest-wall
infiltration and mediastinal invasion by the tumor.
PET has proved to be very effective for the stag-
ing of mediastinal nodes.
 
24
 
 Since PET images have
a fairly high resolution, lesions that are less than
1 cm can be detected. This is a critical advantage
over conventional CT and magnetic resonance im-
aging. However, tracing focal abnormalities to spe-
cific lymph nodes is difficult or even impossible with
the use of PET alone.
 
25
 
 To pinpoint mediastinal le-
sions, PET images must be correlated with CT im-
ages. Several studies have demonstrated that fusion
of images of the trunk obtained by CT and PET from
different scanners is technically possible.
 
26-28
 
 How-
ever, this approach did not increase the accuracy of
mediastinal staging over that obtained by PET alone.
In all these studies, the images from separate scan-
ners were coregistered. Use of the same positions
during PET and CT is important for proper coregis-
tration of the images obtained with separate scan-
ners during whole-body examinations.
To overcome the problems related to the fusion
discussion
 
Figure 1. CT Scan, Attenuation-Corrected PET Scan, and Coregistered PET–CT 
Scan of a Patient with Non–Small-Cell Lung Cancer.
 
The CT scan (Panel A) and the PET scan (Panel B) showed the primary tumor 
in the left upper lobe, indicating that tumor invasion was probable. Tumor in-
vasion was evident on the coregistered PET–CT scan (Panel C). This finding 
was confirmed intraoperatively, resulting in an en-bloc resection of the tumor 
with part of the chest wall.
A
C
B
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of images with the use of software, various proto-
typical systems have been developed that combine
PET and CT. Townsend and his colleagues com-
bined a CT scanner and a partial-ring, rotating PET
scanner in a single gantry.
 
14
 
 Such systems are at-
tractive not only because of their capacity to coregis-
ter images with use of hardware, but also because
the CT data can be used to correct PET scans for ab-
sorption of the emission rays by the patient’s tissues.
This approach obviates the need for the time-con-
suming attenuation correction based on germani-
um-68 transmission sources and decreases the ac-
quisition time by up to 30 percent, depending on the
CT system used.
In our study, integrated PET–CT was clearly su-
perior to the other imaging methods, especially with
regard to tumor stages. The high level of reliability
of integrated PET–CT with respect to identifying hi-
lar lymph nodes, mediastinal lymph nodes, and su-
praclavicular lymph nodes, and providing precise
information on chest-wall or mediastinal invasion
may have therapeutic implications.
Despite the fact that integrated PET–CT im-
proved the accuracy of mediastinal staging, the res-
olution of PET is not sufficient to detect micro-
scopic lymph-node metastases. If the radionuclide
uptake is not increased on PET, integrated PET–CT
will certainly not provide further information. In
our study, two micrometastases and one lymph-
node metastasis of 5 mm were missed in three pa-
tients. These results demonstrate that integrated
PET–CT does not necessarily obviate the need for
mediastinoscopy for mediastinal staging.
Previous studies demonstrated the high accu-
racy of whole-body PET in the detection of unsus-
 
Table 3. Diagnostic Accuracy of the Imaging Methods 
with Respect to Node Stage in 37 Patients.
Imaging 
Method
Classification 
Correct 
(Score of 3)
Classification 
Correct 
but Equivocal 
(Score of 2)
Classification 
Incorrect 
(Score of 
0 or 1)
 
no. of patients (%)
 
CT alone 22 (59) 2 (5) 13 (35)
PET alone 18 (49) 14 (38) 5 (14)
Visual cor-
relation of 
PET and CT
22 (59) 4 (11) 11 (30)
Integrated 
PET–CT
30 (81) 1 (3) 6 (16)
 
Figure 2. CT Scan, Attenuation-Corrected PET Scan, and Coregistered PET–
CT Scan in a Patient with Non–Small-Cell Lung Cancer.
 
No enlarged lymph nodes were seen in the apex of the thorax on CT (Panel A), 
but a focal area of increased radionuclide uptake was found on PET (Panel B). 
The exact location of the lesion remained unclear. Coregistered PET–CT re-
vealed that the area of increased radionuclide uptake matched a normal-sized 
lymph node. Owing to the accumulation of fludeoxyglucose F 18, this lymph 
node was interpreted as a potential site of metastasis. The capacity of PET–CT 
to pinpoint the location of this focal abnormality made possible the precise 
excision of the node. Histologic analysis revealed a 5-mm lymph-node metas-
tasis, and induction chemotherapy was initiated.
A
C
B
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pected extrathoracic metastases.
 
3-6
 
 In various stud-
ies, whole-body PET detected unsuspected M1
disease in 6 to 17 percent of patients (mean, 12 per-
cent)
 
29
 
; in the present study, such metastases were
found in 8 of 49 patients (16 percent). However,
the clinical significance of the finding of a single
focal abnormality on PET remains unclear, espe-
cially when no morphologic alterations are identi-
fied on CT. Integrated PET–CT permits the focal
abnormality to be traced to a specific location, as
exemplified in two of our patients in whom inte-
grated PET–CT identified single-bone metastases.
We used unenhanced CT scans for integrated
PET–CT imaging. We could not ethically justify
the use of vascular contrast material, because all
patients were referred after having undergone con-
ventional contrast-enhanced CT for staging. Fur-
ther evaluation is necessary to determine the con-
ditions in which the use of intravascular contrast
material might have an additional diagnostic im-
pact in integrated PET–CT. However, in the case of
infiltration of hilar and mediastinal vessels, con-
ventional CT with contrast enhancement has a rel-
atively low sensitivity, specificity, and accuracy (68
percent, 72 percent, and 70 percent, respectively).
 
30
 
The main drawback of PET is the poor quality of
the anatomical information, which often precludes
a precise assessment of the tumor and node stage.
In our study, equivocal findings were most com-
mon with PET. The low kappa values for both re-
view boards in assigning stages on the basis of PET
underline the difficulties inherent in the use of this
approach for the determination of tumor and node
stages, particularly with respect to tumor infiltra-
tion of surrounding structures and the exact loca-
tion of single nodes.
Because integrated PET–CT has a faster acqui-
sition time than does a conventional dedicated PET
scanner, the duration of the examination — and
thus of the patient’s discomfort — is decreased. We
used low-dose CT scans that were coregistered
with PET scans. It was recently demonstrated that
coregistration can pinpoint focal abnormalities
with the use of an 80-mA CT scanner, an approach
that keeps the level of exposure to radiation low.
 
17
 
Our data suggest that once integrated PET–CT
becomes more widely available, it will be the pre-
ferred approach for determining the stage of dis-
ease in non–small-cell lung cancer. If the results of
forthcoming studies of larger numbers of patients
confirm our results, integrated PET–CT may be-
come the new standard approach to imaging in pa-
tients with lung cancer.
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